Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2): 15-25.BarbuiTThieleJGisslingerHKvasnickaHMVannucchiAMGuglielmelliPThe 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion201882152510.1038/s41408-018-0054-y580738429426921Search in Google Scholar
Vannucchi AM, Harrison CN. Emerging treatment for classical myeloproliferative neoplasms. Blood. 2017; 129(6): 693-703.VannucchiAMHarrisonCNEmerging treatment for classical myeloproliferative neoplasms2017129669370310.1182/blood-2016-10-69596528028027Search in Google Scholar
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17): 1779-1790.KralovicsRPassamontiFBuserASTeoSSTiedtRPasswegJRA gain-of-function mutation of JAK2 in myeloproliferative disorders2005352171779179010.1056/NEJMoa05111315858187Search in Google Scholar
Singdong R, Siriboonpiputtana T, Chareonsiri-suthigul T, Kongruang A, Limsuwanachot N, Sirirat T, et al. Characterisation and prognosis significance of JAK2 (V617F), MPL and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2016; 17(10): 4647-4653.SingdongRSiriboonpiputtanaTChareonsiri-suthigulTKongruangALimsuwanachotNSiriratTCharacterisation and prognosis significance of JAK2 (V617F), MPL and CALR mutations in Philadelphia negative myeloproliferative neoplasms2016171046474653Search in Google Scholar
Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA, Almosailleakh MR. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann Hematol. 2014; 93(5): 791-796.AlshemmariSHRajaanRAmeenRAl-DreesMAAlmosailleakhMRJAK2V617F allele burden in patients with myeloproliferative neoplasms201493579179610.1007/s00277-013-1988-624362471Search in Google Scholar
Perricone M, Polverelli N, Martinelli G, Catani L, Ottaviani E, Zuffa E, et al. The relevance of a low JAK2 V617F allele burden in clinical practice: A monocentric study. Oncotarget. 2017; 8(23): 37239-37249.PerriconeMPolverelliNMartinelliGCataniLOttavianiEZuffaEThe relevance of a low JAK2 V617F allele burden in clinical practice: A monocentric study2017823372393724910.18632/oncotarget.16744551490628422729Search in Google Scholar
Ha, JS, Kim YK, Jung SI, Jung HR, Chung, IS. Correlations between Janus Kinase 2V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med. 2012; 32(6): 385-391.HaJSKimYKJungSIJungHRChungISCorrelations between Janus Kinase 2V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms201232638539110.3343/alm.2012.32.6.385348693123130336Search in Google Scholar
Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013; 27(10): 2032-2039.JovanovicJVIveyAVannucchiAMLippertEOppliger LeibundgutEEstablishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet MPN&MPNr-EuroNet (COST action BM0902) study201327102032203910.1038/leu.2013.219380625023860450Search in Google Scholar
Malysz J, Crisan D. Correlation of JAK2 V617F mutant allele quantification with clinical presentation and type of chronic myeloproliferative neoplasm. Ann Clin Lab Sci. 2009; 39(4): 345-350.MalyszJCrisanDCorrelation of JAK2 V617F mutant allele quantification with clinical presentation and type of chronic myeloproliferative neoplasm2009394345350Search in Google Scholar
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008; 93(1): 41-48.AntonioliEGuglielmelliPPoliGBoganiCPancrazziALongoGInfluence of JAK2V617F allele burden on phenotype in essential thrombocythemia2008931414810.3324/haematol.1165318166784Search in Google Scholar
Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia Res. 2011; 35(2): 177-182.SilverRTVandrisKWangYLAdrianoFJonesAVChristosPJJAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy201135217718210.1016/j.leukres.2010.06.017362609120650526Search in Google Scholar